Modified cardiometabolic index and stroke risk: Evidence from the CHARLS cohort
Xianhong Wu1, Shiqin Chen1, Tian Lv2
1Department of Neurology, Yuhuan Second People's Hospital, Yuhuan 317605, China.
Insights
Higher modified cardiometabolic index (MCMI) levels are linked to increased stroke risk. While MCMI shows slightly better prediction than the cardiometabolic index (CMI), further validation is needed for clinical use.
Area of Science:
- Cardiology
- Neurology
- Public Health
Background:
- The modified cardiometabolic index (MCMI) is a novel marker, but its association with stroke risk is not well-established.
- Cardiometabolic risk factors are critical in predicting cerebrovascular events.
Purpose of the Study:
- To investigate the relationship between the modified cardiometabolic index (MCMI) and the risk of incident stroke.
- To compare the predictive performance of MCMI against the traditional cardiometabolic index (CMI).
Main Methods:
- A prospective cohort study involving 8167 participants from the China Health and Retirement Longitudinal Study (2011-2020).
- Modified cardiometabolic index (MCMI) calculated using triglycerides, fasting blood glucose, HDL cholesterol, waist circumference, and height.
- Cox proportional hazards regression, restricted cubic spline (RCS) modeling, and time-dependent ROC analysis were employed.
Main Results:
- Higher MCMI levels were significantly associated with an increased risk of stroke (HR=1.32).
- A nonlinear relationship was observed between MCMI and stroke risk (P for nonlinearity=0.002).
- MCMI demonstrated slightly superior predictive performance compared to CMI, particularly at longer follow-up intervals.
Conclusions:
- Elevated MCMI levels are positively associated with incident stroke risk.
- The MCMI shows potential as a predictive marker for stroke, though its clinical utility requires further investigation.
- Large-scale validation studies are necessary before routine clinical application of MCMI for stroke risk stratification.
Abstract:
The association between the modified cardiometabolic index (MCMI) and stroke risk remains unclear. This study aimed to investigate the relationship between MCMI and incident stroke. A total of 8167 participants from the China Health and Retirement Longitudinal Study (baseline 2011) were included. MCMI was calculated as ln[triglycerides × fasting blood glucose/ high-density lipoprotein cholesterol] × waist circumference/ height. Incident stroke was defined as self-reported physician-diagnosed stroke during follow-up through 2020. Cox proportional hazards regression, restricted cubic spline (RCS) modeling, and subgroup analyses were performed to examine the association. Time-dependent receiver operating characteristic (ROC) analysis was used to compare the predictive performance of MCMI with that of the cardiometabolic index (CMI). Over 9 years of follow-up, higher MCMI levels were associated with increased stroke risk (hazard ratio [HR] = 1.32, 95% confidence interval [CI]: 1.20-1.46). Quartile analyses confirmed this trend, with the highest quartile showing the greatest risk compared with the lowest (HR = 2.30, 95% CI: 1.80-2.94). RCS analysis revealed a nonlinear relationship (P for nonlinearity = 0.002). Subgroup analyses suggested potential heterogeneity across marital status and residential location. ROC analysis showed that the MCMI consistently yielded higher AUC values than the CMI at 3 years (0.72 vs 0.70), 5 years (0.75 vs 0.73), 7 years (0.77 vs 0.75), and 8 years (0.72 vs 0.70), with all DeLong's test P-values < 0.05. Higher MCMI levels were positively associated with stroke risk. Although MCMI demonstrated slightly better predictive performance than CMI, the improvement was limited. These findings support an association rather than direct clinical applicability. Additional large-scale prospective studies and validation analyses are required before its routine use in clinical risk stratification can be considered.
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
